Seeking Alpha

Investorideas.com's  Instablog

Investorideas.com
Send Message
www.InvestorIdeas.com is a meeting place for investors and public companies in leading sectors. Find investing ideas, news and research for biotech stocks, tech and mobile stocks, mining stocks, oil and gas, water stocks, renewable energy, beverage stocks, defense stocks, nanotech and more on... More
My company:
Investor Ideas
My blog:
Investor Ideas Newswire
  • Biotech News Alert: SUNSHINE BIOPHARMA (OTCQB: SBFM) EXPANDS DRUG PIPELINE TARGETING PANCREATIC CANCER AS SECOND INDICATION FOR CLINICAL TRIALS OF Adva-27a COMPOUND 0 comments
    Jan 22, 2014 11:20 AM | about stocks: SBFM

    Montreal, Quebec, Canada - January 22, 2014 (Investorideas.com Biotech Newswire) Biopharma alert: Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, reports that it is targeting pancreatic cancer as a second indication for Adva-27a, the Company's flagship anticancer drug candidate. As previously announced (see press release dated June 4, 2013), Adva-27a, a Topoisomerase II inhibitor, was found to be effective at destroying cells of the very aggressive pancreatic cancer cell line, Panc-1. Adva-27a was able to kill these cells with an IC50 of approximately 4 micromolar, a pharmacologically very favorable drug concentration. Based on initial data, the Company is moving forward with intentions to conduct a Phase I clinical trial of Adva-27a for pancreatic cancer in parallel to the planned Phase I clinical trial of Adva-27a for breast cancer that is scheduled to be hosted at McGill University's Jewish General Hospital in Montreal.

    Full news: http://www.investorideas.com/CO/SBFM/news/2014/01211.asp

    January 21 st Close : $0.20 Up 0.03(14.29%)

    Investorideas.com Newswire

    About Adva-27a

    Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells, small-cell lung cancer cells, uterine sarcoma cells and pancreatic cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935.

    Investorideas.com Newswire

    About Sunshine Biopharma Inc.

    Sunshine Biopharma is an early stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. Sunshine Biopharma recently announced that it has initiated IND-Enabling studies for its lead antitumor compound, Adva-27a, which is currently targeted for multidrug resistant cancer.

    Safe Harbor Forward-Looking Statements

    To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

    For Additional Information Contact:

    Camille Sebaaly, CFO
    Sunshine Biopharma Inc.
    Direct Line: 514-814-0464
    camille.sebaaly@sunshinebiopharma.com

    www.sunshinebiopharma.com

    Themes: biotech Stocks: SBFM
Back To Investorideas.com's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.